- Home
- CHRS vs CRBU Comparison
CHRS vs CRBU Comparison
Compare CHRS & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- CRBU
- Stock Information
- Founded
- CHRS 2010
- CRBU 2011
- Country
- CHRS United States
- CRBU United States
- Employees
- CHRS N/A
- CRBU N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- CRBU Medicinal Chemicals and Botanical Products
- Sector
- CHRS Health Care
- CRBU Health Care
- Exchange
- CHRS Nasdaq
- CRBU Nasdaq
- Market Cap
- CHRS 94.0M
- CRBU 93.0M
- IPO Year
- CHRS 2014
- CRBU 2021
- Fundamental
- Price
- CHRS $0.91
- CRBU $0.86
- Analyst Decision
- CHRS Strong Buy
- CRBU Strong Buy
- Analyst Count
- CHRS 4
- CRBU 5
- Target Price
- CHRS $5.38
- CRBU $11.80
- AVG Volume (30 Days)
- CHRS 2.1M
- CRBU 972.0K
- Earning Date
- CHRS 05-08-2025
- CRBU 05-06-2025
- Dividend Yield
- CHRS N/A
- CRBU N/A
- EPS Growth
- CHRS N/A
- CRBU N/A
- EPS
- CHRS 0.25
- CRBU N/A
- Revenue
- CHRS $266,959,999.00
- CRBU $9,994,000.00
- Revenue This Year
- CHRS N/A
- CRBU N/A
- Revenue Next Year
- CHRS $9.02
- CRBU $163.34
- P/E Ratio
- CHRS $3.66
- CRBU N/A
- Revenue Growth
- CHRS 3.78
- CRBU N/A
- 52 Week Low
- CHRS $0.66
- CRBU $0.72
- 52 Week High
- CHRS $2.61
- CRBU $4.92
- Technical
- Relative Strength Index (RSI)
- CHRS 45.16
- CRBU 34.25
- Support Level
- CHRS $0.89
- CRBU $0.88
- Resistance Level
- CHRS $1.07
- CRBU $1.01
- Average True Range (ATR)
- CHRS 0.09
- CRBU 0.09
- MACD
- CHRS -0.00
- CRBU -0.00
- Stochastic Oscillator
- CHRS 44.79
- CRBU 42.24
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer. Coherus is developing an innovative immuno-oncology pipeline which includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.